The central focus of the Cytogenetics Core (CYT) is to provide high quality cytogenetic and molecular cytogenetic analysis of human and animal model research samples. The CYT provides specialized services to members of the Mayo Clinic Cancer Center (MCCC) and other investigators within the Mayo research community. Services include: Cell Culture, Routine Chromosome Analysis, DNA and RNA fluorescence in situ Hybridization (FISH), Spectral Karyotyping (SKY) Analysis of human and mouse metaphases, and Custom DNA Probe Production. The service line has recently been enhanced through the development of an RNA FISH Probe Production line and a Tyramide Signal Amplification (TSA) protocol. Together, with the investigator, the CYT assists in determining how these techniques can be utilized to meet the evolving needs of their research studies. The CYT then assists in the translation of these novel assays toward employment as clinical diagnostic tests and prognostic markers of disease, as relevant. In addition to the test menu described above, the CYT staff also provides specialized training to investigators for FISH set-up, and microscope use in an effort to minimize investigator cost and economize technologist time. The technologists that make up the CYT have over 70 years of combined cytogenetic expertise. The CYT has a total of 99 users for this grant cycle, representing 10 of the 10 Cancer Center programs active at the time. Among our 99 users, 73 (74%) are Cancer Center members. Of these 73 investigators, 50 (68%) have active peer-reviewed funding. Many MCCC scientists at the forefront of genetic cancer research require both conventional and molecular cytogenetic techniques to advance their studies. The depth of knowledge and diverse expertise of the CYT staff provides an invaluable resource to investigators looking to move their research forward. Comprehensive cytogenetic and molecular cytogenetic testing and interpretation is not offered in any other core or research laboratory at Mayo Clinic. It is the CYT's deep commitment to working with the investigator to meet their unique scientific needs that enables the CYT to continue to be an invaluable resource to Mayo Clinic Cancer Center members.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33
Bogenberger, James M; Delman, Devora; Hansen, Nanna et al. (2015) Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma 56:226-9
Sami, Sarmed S; Ragunath, Krish; Iyer, Prasad G (2015) Screening for Barrett's esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol 13:623-34
Boland, Jennifer M; Wampfler, Jason A; Jang, Jin S et al. (2014) Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. Am J Surg Pathol 38:1681-8
Imperiale, Thomas F; Ransohoff, David F; Itzkowitz, Steven H et al. (2014) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370:1287-97
Fackler, Mary Jo; Lopez Bujanda, Zoila; Umbricht, Christopher et al. (2014) Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res 74:2160-70
Porrata, Luis F; Ristow, Kay M; Habermann, Thomas M et al. (2014) Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma 55:2728-38
Yoon, Harry H; Tougeron, David; Shi, Qian et al. (2014) KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 20:3033-43
Espejo, Rosario; Jeng, Yowjiun; Paulucci-Holthauzen, Adriana et al. (2014) PTP-PEST targets a novel tyrosine site in p120 catenin to control epithelial cell motility and Rho GTPase activity. J Cell Sci 127:497-508
Banck, Michaela S; Beutler, Andreas S (2014) Advances in small bowel neuroendocrine neoplasia. Curr Opin Gastroenterol 30:163-7

Showing the most recent 10 out of 340 publications